Total Price: $0.00
Contact Information
Recombinant Human MMP-2 Protein (Active)
SKU: PKSH031888-100
Recombinant Human MMP-2 Protein (Active)
| SKU # | PKSH031888 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | 72 kDa Gelatinase, 72 kDa Type IV Collagenase, CLG4, CLG4A, Gelatinase A, MMP-2, MMP-II, MMP2, MONA, Matrix Metalloproteinase-2, TBE-1 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Cys 660 |
| Accession | NP_004521.1 |
| Calculated Molecular Weight | 72 kDa |
| Observed Molecular Weight | 72 kDa |
| Tag | None |
| Bio-activity | 1. Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2 (AnaSpec, Catalog # 27076). The specific activity is > 1, 000 pmoles/min/µg. 2. Immobilized human MMP2 at 10 μg/mL (100 μl/well) can bind human TIMP2/Fc. The EC50 of human TIMP2/Fc is 0.02 μg/mL. (Activation description: The proenzyme needs to be activated by APMA for an activated form) |
Properties
| Purity | > 90 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN); Her2/neu; growth factors; cytokines; and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor; usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity; MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems; including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.